The value of post-operative radiotherapy as an adjuvant to surgery for patients with non-small-cell lung cancer still remains to be proven in a disease which is still at present a major cause of cancer death in man. It is, therefore, with regret that one has to conclude that the publication in this issue (Medical Research Council Lung Cancer Working Party, 1996) has not answered this relevant question, as the authors have approached this question yet again in a small randomised trial. This is the more frustrating as it is already the sixth trial in succession which is open to criticism, i.e. a limited number of patients have been entered, low radiation doses have been used, there were a large number of ineligible patients, there was inappropriate staging and no quality assurance programme to guarantee adequate treatment. It is remarkable, however, to see that an improvement in time to definite local recurrence and distant metastases is observed in N2 patients where only 36% of the 154 patients allocated to radiotherapy received the treatment as specified in the protocol.
The question of the value of post-operative radiotherapy needs, however, to be answered more adequately. Even a small benefit in survival ranging from 5-10% would already rescue a large number of patients in absolute terms. To be able to prove or disprove an improvement of between 5 and 10% in 5-year survival, one needs to randomise at least 1000 to 4000 patients (Freedman, 1982) . Much larger numbers are required if one plans to perform subgroup analysis, as the authors have done. To identify subgroups, such as N2 patients, who will benefit most from this adjuvant approach, one would need a few thousand patients.
Despite these comments, the authors deserve credit for having pursued a randomised trial in an area where no major progress has been seen during the last decades. Although the trial lacks statistical power to prove or disprove a survival benefit, it has shown a significant improvement in time to definite local recurrence and the appearance of distant metastases. It is obvious that improvement in local control is beneficial in patients with lung cancer, as will be acknowledged by physicians who deal daily with these patients and often fail to reduce symptoms of airway obstruction. It is even remarkable that this present trial was able to demonstrate an improvement in local control with the low radiation dose given and a suboptimal technique. One should also recognise here that, recently, a number of lung cancer trials have been published showing that improved local control has resulted in a higher survival rate. These trials even included patients with more advanced disease and therefore a higher risk of distant metastases than the trial published in this issue. This improvement in local control has been reached, for example, by modifying the radiation effects by dose escalation (Cox et al., 1991) or the daily addition of cisplatin (Schaake-Koning et al., 1992) or acceleration of the radiation treatment by reducing the overall treatment time from 6 to 2 weeks (MI Saunders, personal communication).
Unless a trial of appropriate size is organised to assess the effect of post-operative radiotherapy on local control and its impact on survival, the question will remain unanswered.
